The U.S. Supreme Court’s decision to uphold the Constitutionality of Obamacare by a 5-4 vote will mean different things to different people.
Even its impact on healthcare companies will vary. Health insurers will face pricing pressure, although those that benefit from Medicaid spending stand to benefit from increased funding. However, the ruling limited the law’s plans to expand Medicaid, determining that the federal government cannot without a state’s entire Medicaid allotment if it fails to participate in Obamacare.
Medical device companies, likewise could feel some strain, while manufacturers of diagnostic tests and hospitals could benefit.